Personalis EPS - Earnings per Share 2018-2025 | PSNL

Personalis eps - earnings per share from 2018 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Personalis Annual EPS
2024 $-1.37
2023 $-2.25
2022 $-2.48
2021 $-1.49
2020 $-1.20
2019 $-1.39
2018 $-6.49
2017 $-7.78
Personalis Quarterly EPS
2025-03-31 $-0.18
2024-12-31 $-0.23
2024-09-30 $-0.64
2024-06-30 $-0.24
2024-03-31 $-0.26
2023-12-31 $-0.54
2023-09-30 $-0.60
2023-06-30 $-0.50
2023-03-31 $-0.61
2022-12-31 $-0.67
2022-09-30 $-0.58
2022-06-30 $-0.60
2022-03-31 $-0.63
2021-12-31 $-0.46
2021-09-30 $-0.40
2021-06-30 $-0.34
2021-03-31 $-0.29
2020-12-31 $-0.35
2020-09-30 $-0.27
2020-06-30 $-0.29
2020-03-31 $-0.29
2019-12-31 $1.56
2019-09-30 $-0.22
2019-06-30 $-0.89
2019-03-31 $-1.84
2018-12-31 $0.00
2018-09-30 $-1.19
2018-06-30 $-2.39
2017-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.581B $0.085B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.223B 6.87
Dr Reddy's Laboratories (RDY) India $12.581B 22.83
BridgeBio Pharma (BBIO) United States $8.518B 0.00
Bausch Health Cos (BHC) Canada $2.391B 1.72
Supernus Pharmaceuticals (SUPN) United States $1.745B 14.16
Amphastar Pharmaceuticals (AMPH) United States $1.088B 7.30
Taysha Gene Therapies (TSHA) United States $0.511B 0.00
Assembly Biosciences (ASMB) United States $0.132B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00